Therapy News and Research

RSS

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

Oxytocin maintains bond between loving couples, promotes monogamy

How is the bond between people in love maintained? Scientists at the Bonn University Medical Center have discovered a biological mechanism that could explain the attraction between loving couples.

26 Nov 2013

Expert offers tips for families to avoid sensory processing disorders during holiday travels

While holiday travels can be stressful for any family, the season presents greater challenges for families of children with sensory processing disorders. Varleisha Gibbs OTD, OTR/L, director of doctoral projects and assistant professor of occupational therapy at University of the Sciences in Philadelphia, said attempting to coordinate a child's sensory, dietary, and energy needs while traveling can make a holiday getaway seem like a full-time job.

26 Nov 2013

Sacral neuromodulation stands test of time in LUTD

Follow-up of patients at a Belgian institution reveals that sacral neuromodulation is effective for the treatment of lower urinary tract dysfunction over the long term, but often requires reintervention.

From Medtronic 25 Nov 2013

First symptom predicts urodynamic diagnosis in MUI

Researchers have found that the first or most bothersome symptom in women with mixed urinary incontinence closely relates to the urodynamic diagnosis.

25 Nov 2013

New diabetes has little impact on outcomes in elderly hypertensives

Established, but not newly diagnosed, diabetes is associated with reduced survival among elderly patients with hypertension, shows an analysis of the ANBP2 study.

25 Nov 2013

Anti-epileptic drugs, bone loss and supplements

Antiepileptic drugs are medications used to prevent and control seizure disorders. These medications are also frequently used for other diagnoses other than seizures, however this current study concentrated on patients with a seizure disorder.

25 Nov 2013

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

Living Cell Technologies Limited today announced that the independent data safety monitoring board has reviewed the safety data from the initial patient in the Phase I/IIa clinical trial of NTCELL and advised that implants for the additional three patients in the trial can proceed.

25 Nov 2013

Radiation therapy now available via latest version of ACR ppropriateness Criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

25 Nov 2013

CRISPR-Cas-system: A promising tool for genetic engineering

Viruses cannot only cause illnesses in humans, they also infect bacteria. Those protect themselves with a kind of 'immune system' which - simply put - consists of specific sequences in the genetic material of the bacteria and a suitable enzyme. It detects foreign DNA, which may originate from a virus, cuts it up and thus makes the invaders harmless.

25 Nov 2013

New study led by CDC reports nearly half of US children are diagnosed with ADHD

A new study published in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) found that an estimated two million more children in the United States (U.S.) have been diagnosed with attention-deficit/hyperactivity disorder (ADHD) between 2003-04 and 2011-12.

25 Nov 2013

Super cocktail of six natural compounds killed 100% of breast cancer cells without toxic side effects

A study led by Madhwa Raj, PhD, Research Professor in Obstetrics and Gynecology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, has found that a super cocktail of six natural compounds in vegetables, fruits, spices and plant roots killed 100% of sample breast cancer cells without toxic side effects on normal cells.

25 Nov 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Novel drug combats psychosis in Parkinson’s disease

The non-dopaminergic drug pimavanserin reduces psychotic symptoms in patients with Parkinson’s disease without worsening motor function, shows a randomized trial.

22 Nov 2013

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.

22 Nov 2013

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.

22 Nov 2013

New documentary reveals how antiretroviral therapy transformed lives of HIV people in Africa

A new documentary produced by the University of East Anglia reveals how the lives of people with HIV in Africa have been transformed by antiretroviral therapy and highlights the crucial need for continued funding of the lifesaving treatment.

22 Nov 2013

Therapy News and Research

SillaJen executes definitive merger agreement to acquire Jennerex

Oxytocin maintains bond between loving couples, promotes monogamy

Expert offers tips for families to avoid sensory processing disorders during holiday travels

Sacral neuromodulation stands test of time in LUTD

First symptom predicts urodynamic diagnosis in MUI

New diabetes has little impact on outcomes in elderly hypertensives

Anti-epileptic drugs, bone loss and supplements

DSMB reviews safety data from Phase I/IIa clinical trial of NTCELL for Parkinson’s disease

Radiation therapy now available via latest version of ACR ppropriateness Criteria

CRISPR-Cas-system: A promising tool for genetic engineering

New study led by CDC reports nearly half of US children are diagnosed with ADHD

Super cocktail of six natural compounds killed 100% of breast cancer cells without toxic side effects

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Novel drug combats psychosis in Parkinson’s disease

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

New documentary reveals how antiretroviral therapy transformed lives of HIV people in Africa

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News